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Introduction 1 53
Dynamic HIV transmission models are used to guide implementation of HIV prevention and 54 treatment interventions, estimate the cost and cost-effectiveness, and explore the potential impact of 55 new strategies [1] [2] [3] . In principle, HIV models incorporate prevention interventions, such as behavioral 56 changes, medications, or vaccines, based on known mechanisms of action or assumptions about how each 57 intervention achieves its preventive effect. However, although HIV viral load is the primary predictor of 58 HIV transmission, [4] few population modeling studies of HIV include a detailed description of the 59 dynamics of HIV viral load along stages of HIV disease progression [5] . A potential modeling approach is 60 nesting stochastic algorithms using Markov chain for HIV disease progression (i.e., changes in viral load 61 and CD4 count over time) into HIV transmission models [6] . These estimates of changes in HIV viral load 62 and CD4 count are particularly applicable when modeling interventions that exert a preventive effect by 63 reducing HIV viral load. 64
While universal treatment with antiretroviral therapy (ART) is the most effective strategy for 65 reducing HIV viral load and onward transmission [7, 8] , 72% of HIV-positive people in western and central 66 Africa and 46% of HIV-positive people in eastern and southern Africa lack access to ART [9] , suggesting 67 that adjunctive strategies to slow disease progression and prevent HIV transmission may b e beneficial in 68 these settings. Suppression of herpes simplex virus type two (HSV-2) in persons co-infected with HIV who 69
are not yet on ART has been explored as an adjunctive tool for HIV prevention because HIV-HSV-2 co-70 infected individuals have faster CD4 count decline, increased HIV viral load and increased risk of onward 71 transmission of HIV as compared to HIV mono-infected individuals [10, 11] . A previous study of the impact 72 of HSV-2 suppression on HIV progression in co-infected individuals (the Partners in Prevention HSV/HIV 73 Transmission Study) found that acyclovir 400mg, taken twice daily, did not reduce HIV transmission 74 between HIV serodiscordant heterosexual couples, despite lowering viral load by 0.25 log copies/mL and 75 reducing the occurrence of HSV-2 positive genital ulcers by 73% [11] . However, administration of twice 76 daily high-dose (1.5g) valacyclovir, an acyclovir pro-drug, to HIV-HSV-2 co-infected individuals achieved a 77 76% HIV viral load reduction compared with treatment with acyclovir [12] . This finding raises the 78 possibility that valacylovir could also impact HIV progression and transmission differently than acyclovir. 79
Dynamic transmission modeling allows for estimation of how the additional reduction of HIV viral load 80 achieved with valacyclovir could impact HIV progression, transmission, and at what programmatic cost. 81
Here, we report on a three step modeling investigation into the impact of co-infection treatment 82 a prospective placebo-controlled randomized study, enrolled 3,408 serodiscordant couples from eastern 95 and southern Africa, in which the HIV-positive partner was ART-naïve and co-infected with HSV-2. The 96 study evaluated the impact of HSV-2 suppression with acyclovir for the HIV-positive partner on HIV 97 transmission [11] . The Partners PrEP Study, a prospective placebo-controlled randomized study, enrolled 98 4,758 serodiscordant couples from East Africa in which the HIV-infected partner was ART-naïve. While the 99 primary objective of Partners PrEP was to evaluate the impact of pre-exposure prophylaxis for HIV-100 uninfected partners on HIV acquisition, CD4 and viral load were also measured at six-month intervals for 101 individuals who acquired HIV infection. Nearly 56% of the HIV-negative partners were seropositive for 102 HSV-2 at enrollment [8] . We included all CD4 and HIV viral load follow-up data for both studies from 103 partners who were HIV-negative at enrollment and seroconverted during the study period. 104
Data: 105
CD4 count and viral load were measured at the beginning and end of all 6 and 12-month intervals 106 post-seroconversion and used for this analysis. For intervals that ended with ART initiation, the CD4 count 107 and VL were estimated by the aggregate distribution of CD4 and viral load measurements ≤3 months prior 108 to ART initiation. There were 151 HIV seroconverters in the Partners in Prevention HSV/HIV Transmission 109 Study and 138 HIV seroconverters in the Partners PrEP Study [8, 11] . 110
Analysis of Disease Progression: 111
To estimate disease progression among HIV-infected individuals, we organized individuals into 112 discrete CD4 and viral load categories. The amount of time spent in each CD4 and viral load category was 113 then estimated by applying discrete-time Markov models for CD4 and viral load, and calculating the time 114 to absorption ( Fig. 1 ). Only observations with simultaneous CD4 and viral load measurements were 115 included in the analysis. The proportions of individuals progressing from one CD4 and viral load category 116 to another were assumed to form the transition matrix for progression from one category to another. For 117 CD4 cell progression, we calculated the average time from CD4>500 cells/µL to absorption in each of the 118 subsequent CD4 categories. The duration in each category was estimated to be the difference between 119 times to absorption for adjacent absorption scenarios. A similar process was used for viral load 120 progression, but with starting viral load of <1,000 copies/mL. infected, or HSV-2 suppressed with valacyclovir prophylaxis. At baseline, we assume no valacyclovir 148
prophylaxis is used and that 60% of HIV infected men are co-infected with HSV-2, and 80% of HIV-infected 149 women are co-infected with HSV-2 [20]. HSV-2 infection is assumed to increase HIV transmission and HIV 150 acquisition as estimated in a previous meta-analysis [20] (Table 1 ). The age-specific HIV incidence and 151 prevalence were validated with independent South African national survey data [25] . 152
Valacyclovir intervention scenarios: 153
We assessed the impact of valacyclovir prophylaxis on HIV progression and HIV transmission in 154 three scenarios ( Table 2 ). The baseline scenario assumes that valacyclovir is not provided, and that 155 persons become eligible for ART when their CD4 falls below 500. The valacyclovir scenario assumes that 156 48% of individuals with CD4≤500 cells/µL and not using valacyclovir are on ART, with the initiation of 157 valacyclovir leading to a 25% increase in ART coverage (60%), due to retention in pre-ART care and more 158 rapid initiation of ART when an individual's CD4 count falls below 500 cells/µL. The final scenario assumes 159 a Test and Treat program where 70% of all HIV-positive individuals are on ART, and no one is taking 160 valacyclovir prophylaxis. All scenarios assume that home-based HTC is a platform for reaching individuals, 161 which reaches a greater proportion of individuals in a given community than strictly facility-based 162 programs. We assumed that for HSV-2/HIV co-infected persons, valacyclovir prophylaxis reduces viral load 163 by 1.23 log copies/mL, as observed previously, thus slowing CD4 progression [12] . In the first scenario, 164 persons using valacyclovir were assumed to be on valacyclovir for five years, or until ART initiation. 165 The overall durations of each disease stage by CD4 and viral load are shown in Table 3 . Excluding 189 acute infection, the average times spent with CD4>500 cells/µL, CD4 350-500 cells/µL, and CD4 200-350 190 cells/µL are 1.88 years, 1.22 years, and 5.90 years, respectively. The duration of disease after acute 191 infection and before reaching CD4 200 cells/µL is 2.53 years longer for females than males. After assuming 192 a three-month duration for acute infection and including estimates for mortality at each stage and for 193 CD4≤200 cells/µL, overall life expectancy is estimated to be 11.58 years for females and 9.23 years for 194 males. 195 Excluding acute infection, the average times spent with viral load ≤1,000 copies/mL, 1,000-10,000 196 copies/mL, and 10,000-50,000 copies/mL are 3.13 years, 1.99 years, and 4.40 years, respectively. The 197 duration of disease after acute infection and before reaching viral load >50,000 copies/mL is 2.85 years 198 longer for females than for males. 199 
Validation of Disease Progression Estimates: 206
With the disease progression estimates input as parameters in a mathematical model of 207 heterosexual HIV transmission in KwaZulu-Natal, we determined the cross-sectional distribution of CD4 208 count and HIV viral load. We estimated that in 2012, the proportion of HIV-positive persons with CD4 209 counts <200, 200-350, 350-500, and >500 cells/µL were 12%, 38%, 19%, and 31%, which we found to be 210 similar to estimates from KwaZulu-Natal, South Africa, of 11%, 22%, 25%, and 42%. The model also 211 estimated the proportion of HIV-positive persons with viral load >50000, 10000-50000, 1000-10000, and 212 <1000 copies/mL to be 22%, 23%, 12%, and 38%, which we found to be similar to estimates of 24%, 22%, 213 29%, and 25% (Fig. 2) 
Estimated Impact and Cost-Effectiveness of Valacyclovir on HIV Disease Progression and Transmission 220
Relative to a baseline of community HTC, valacyclovir with increased linkage to care results in 221 166,000 fewer HIV infections over ten years, with an incremental cost-effectiveness ratio (ICER) of $4,696 222 per HIV infection averted (Table 4 ). The Test and Treat scenario of 70% ART coverage and no valacyclovir 223 results in 202,000 fewer HIV infections at an ICER of $6,579, which is less than three times the per capita 224 gross domestic product of South Africa and considered cost-effective. 225
Although valacyclovir is expected to prevent infections, it results in a reduction in quality-adjusted 226 life-years (QALY) relative to baseline, due to slowing of CD4 decline and thus delaying ART eligibility in 227 settings without universal eligibility for ART. The Test and Treat scenario, however, increases QALYs at an 228 ICER of $570 per QALY gained relative to baseline. 229 In this multi-part study, we first estimated HIV disease progression using data from two previous 235 clinical trials fit to a discrete-time Markov model. Then, we validated and applied our disease progression 236 findings to estimate the impact of valacyclovir prophylaxis taken by HIV-HSV-2 co-infected persons on HIV 237 disease progression and transmission in a dynamic transmission model. In estimating disease progression, we found that women progress through the course of HIV disease more slowly than men, resulting in a 239 longer life expectancy following seroconversion than men. Most of the additional time spent living with 240 HIV for women is spent in the later stage of HIV infection (CD4 200 to 350 cells/µL and viral load 10,000 241 to 50,000 copies/mL). Estimating these HIV viral load values allowed us to further estimate the impact of 242 providing valacyclovir to HIV-HSV-2 co-infected patients on onward transmission of HIV. Using our model 243 of HIV transmission, we found that valacyclovir prophylaxis was a cost-effective strategy for averting HIV 244 transmission and subsequent new infections. However, unintuitively the valacyclovir strategy reduced 245
QALYs due to the slower CD4 decline and delay in ART eligibility among persons who were taking it. A test 246 and treat scenario of 70% ART coverage without CD4 eligibility criteria was found to be the most cost-247 effective strategy. 248
Disease progression modeling in context 249
Our modeled estimates of HIV disease progression are similar to those found in observational 250 studies. In HIV-infected adults in Cote d'Ivoire and Uganda, the median time from seroconversion to 251 CD4<350 cells/µL was 3.2 years, and from CD4<350 cells/µL to death was 7.6 years, which were similar to 252 our estimates of 3.35 years and 7.86 years, respectively [27] . Two studies of European cohorts also found 253 similar estimates. In the CASCADE Collaboration of primarily European individuals, estimates of 3.80 years 254 from seroconversion to CD4<350 cells/µL and 7.10 years to CD4<200 cells/µL were similar to our estimates 255 of 3.35 and 9.25 years, respectively [28] . The time from seroconversion to CD4<350 cells/µL was estimated 256 to be shorter for Dutch MSM who acquired HIV infection in 2003 -2007 versus in 1984 -1995 , with the 257 estimate for 2003 -2007 varying between 2.2 and 3.0 years between three different methods of calculation 258 [29] . 259
Previous observational studies have also found that women have slower disease progression than 260
men. An analysis of the CASCADE Collaboration found that women have a relative risk of 0.76 of progressing to AIDS and a 0.68 relative risk of progressing to death relative to men [30] . Viral load has also 262 been estimated to be lower in females than males at all CD4 levels in a cohort of intravenous drug users 263 in the USA [31] , as well as to increase at a slower rate in women than in men in an African cohort [32] . 264
However, other studies have found no difference in CD4 count and progression between men and women 265 [33] . Differences in results may be due to variable progression by HIV subtype [34, 35] that nearly 10% of all HIV cases can be attributed to HSV-2 infection [37] . 281
Strengths and limitations of this study 282
A primary contribution of this study is developing a novel Markov model of HIV disease 283 progression through CD4 and VL categories that generates cross-sectional CD4 and viral load prevalences 284 which compare well with observed data. While the estimates were generally similar, the model did 285 estimate that a larger proportion of the HIV-positive population would fall within the VL<1,000 category, 286 relative to the observed data from KwaZulu-Natal (38% versus 25%), and a smaller proportion of the 287 population to fall within the VL 1,000 -10,000 category (12% versus 29%). This may be due to the 288 structure of the model, where all individuals entered the VL <1000 category after acute infection. 289
However, adjusting the modeled population viral load distribution to more closely match the Natal data could be expected to further increase the benefit of the universal test and treat scenario, due 291 to the efficacy of ART in reducing viral load and averting additional HIV transmissions. Additionally, 292 although the data used to fit the Markov model were limited to recent HIV seroconverters rather than the 293 general population of HIV positive persons, estimates of disease progression from seroconverters have 294 been previously extrapolated to the general seroprevalent population [38] . 295
Another strength of this analysis is that the datasets used to estimate the disease progression 296 came from cohorts with high prevalence on HSV-2 seropositivity. These estimates would be generalizable 297 to the many populations with high rates of HIV-HSV-2 co-infection [20], but may not apply as well to 298 populations with low prevalence of HSV-2 infection. Finally, a major driver of our cost estimates were 299 medication. Although our values were rigorously researched estimates, exact costs frequently change, 300 particularly with costs decreasing in the near future. 301
Future directions 302
As more national health programs adopt the WHO recommendation for universal ART eligibility, 303 there will be additional opportunities to use models of disease progression to predict how expansion of 304 ART in different care models will impact the epidemic. Understanding differences in disease progression 305 by sex and by co-infection status will be important to include in these estimates. Models that explicitly include disease progression can be used to estimate the impact of therapeutic vaccines which a im to 307 decrease the progression of HIV. 308
Conclusion 309
Our finding that universal ART access achieves the greatest QALY gains supports current WHO 310 goals of extending ART to all HIV-infected persons. Using validated estimates of disease progression in 311 this model allowed us to estimate the population-level impact of a drug that slows disease progression. 312
Even when compared with initiation of a safe drug (valacyclovir) that could potentially reduce HIV 313 transmission in a setting of high HSV-2 prevalence, universal treatment for HIV is the optimal strategy for 314 increasing QALYs and public health benefit. Universal HIV treatment should be pursued by all countries to 315 most effectively and efficiently reduce the HIV burden. 316
